AltheaDx Nets $6M in Series A Financing | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics developer AltheaDx said today that it has reeled in $6 million in a Series A round of equity financing led by Telegraph Hill Partners of San Francisco.

AltheaDx will use the funds to support its partnerships with biopharmaceutical firms focused on developing companion diagnostics and biomarkers for use in making therapeutics safer, AltheaDx Co-founder and Co-CEO Magda Marquet said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.